argenx SE (ARGX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $785.00, but acceptable to hold if already in. Reason: Earnings in 6 days (event risk).
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP),... Read more
Hold if already holding. Not a fresh buy at $785.00, but acceptable to hold if already in. Reason: Earnings in 6 days (event risk). Chart setup: RSI 46 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $785.00, but acceptable to hold if already in. Reason: Earnings in 6 days (event risk). Chart setup: RSI 46 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $927.89 (+18.2%), stop $746.45 (−5.2%), A.R:R 2.7:1. Score 5.9/10, moderate confidence.
Take-profit target: $927.89 (+18.1% upside). Target $927.89 (+18.2%), stop $746.45 (−5.2%), A.R:R 2.7:1. Stop-loss: $746.45.
Earnings in 6 days (event risk).
argenx SE trades at a P/E of 39.7 (forward 23.4). TrendMatrix value score: 4.5/10. Verdict: Hold.
25 analysts cover ARGX with a consensus score of 4.2/5. Average price target: $1031.
What does argenx SE do?argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in...
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.